Disease · MONDO_0002108
Comparisons in its trials14
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 14 of 14
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Selumetinib 75 mg BD + RAI vs Placebo + RAI: deaths from any cause | 1 of 155 | 2 of 78 | 233 | NCT01843062 | Trial comparisons |
| Selumetinib 75 mg BD + RAI vs Placebo + RAI: serious adverse events | 7 of 154 | 0 of 77 | 231 | NCT01843062 | Trial comparisons |
| Cabozantinib vs Placebo: deaths from any cause | 17 of 125 | 14 of 62 | 187 | NCT03690388 | Trial comparisons |
| Cabozantinib vs Placebo: serious adverse events | 43 of 125 | 18 of 62 | 187 | NCT03690388 | Trial comparisons |
| Arm I (Selumetinib, Iodine I-131) vs Arm II (Placebo, Iodine I-131): deaths from any cause | 0 of 28 | 0 of 30 | 58 | NCT02393690 | Trial comparisons |
| Arm I (Selumetinib, Iodine I-131) vs Arm II (Placebo, Iodine I-131): serious adverse events | 2 of 28 | 1 of 30 | 58 | NCT02393690 | Trial comparisons |
| Arm I (Selumetinib, Iodine I-131) vs Arm II (Placebo, Iodine I-131): Incidence of Adverse Events | 6 of 28 | 1 of 29 | 57 | NCT02393690 | Trial comparisons |
| Arm I (Selumetinib, Iodine I-131) vs Arm II (Placebo, Iodine I-131): Response at 6 Months | 7 of 28 | 2 of 29 | 57 | NCT02393690 | Trial comparisons |
| Arm I (Selumetinib, Iodine I-131) vs Arm II (Placebo, Iodine I-131): Overall Response Rate | 7 of 28 | 2 of 29 | 57 | NCT02393690 | Trial comparisons |
| Cohort A (Iodine I-124 PET/CT, Trametinib, Iodine I-131) vs Cohort B (Iodine I-124 PET/CT, Trametinib, Iodine I-131): deaths from any cause | 6 of 25 | 1 of 9 | 34 | NCT02152995 | Trial comparisons |
| Cohort A (Iodine I-124 PET/CT, Trametinib, Iodine I-131) vs Cohort B (Iodine I-124 PET/CT, Trametinib, Iodine I-131): serious adverse events | 6 of 25 | 1 of 9 | 34 | NCT02152995 | Trial comparisons |
| Anaplastic Thyroid Cancer vs Poorly Differentiated/Variants of Thyroid Cancer: deaths from any cause | 2 of 4 | 1 of 3 | 7 | NCT03002623 | Trial comparisons |
Anaplastic Thyroid Cancer vs Poorly Differentiated/Variants of Thyroid Cancer: Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0) | 4 of 4 | 3 of 3 | 7 | NCT03002623 | Trial comparisons |
| Anaplastic Thyroid Cancer vs Poorly Differentiated/Variants of Thyroid Cancer: serious adverse events | 2 of 4 | 1 of 3 | 7 | NCT03002623 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002108/comparisons